权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cerebrovascular Disease in Sickle Cell Anemia

镰状细胞性贫血中的脑血管疾病

基本信息

批准号：
7391096
负责人：
NORMA B. LERNER
金额：
$ 12.07万
依托单位：
UNIVERSITY OF ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2004
资助国家：
美国
起止时间：
2004-04-01 至 2010-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7391096
关键词：
Age Angiography Appearance Aspirin CCL4 gene Cerebrovascular Disorders Child Childhood Chronic Classification Clinical Clinical Investigator Clinical Research Clinical Trials Coagulation Process Cognitive deficits Daily Data Disease Doppler Ultrasound Dose Ensure Environment Fellowship Funding Future Grant Hemoglobin SS Hemoglobinopathies House Staffs Image Incidence Individual Infarction Inflammation Instruction Investigation Laboratories Laboratory Markers Magnetic Resonance Imaging Magnetism Medical Medical center Mentors Mentorship Modification Neurocognitive Neurocognitive Deficit Neurologic Neurology Numbers Outcome Measure Pain Participant Patients Pediatric Hematologist/Oncologist Pediatric Hematology/Oncology Performance Phase Phase III Clinical Trials Pilot Projects Population Postdoctoral Fellow Predisposition Prophylactic treatment Public Health Qualifying Randomized Recruitment Activity Research Research Personnel Research Training Resources Risk Factors Safety Score Secondary to Series Sickle Cell Anemia Stroke System Testing Time Transfusion Universities Vascular Diseases Work acute chest syndrome cerebrovascular comparison group design experience improved interest member neurocognitive test patient oriented patient oriented research pilot trial prognostic programs success trend

项目摘要

DESCRIPTION (provided by applicant): Candidate - Dr. Lerner is a pediatric hematologist/oncologist who has recently redirected her focus to patient-oriented investigation. She has completed the course work for an MPH degree and has established working relationships with experienced clinical investigators at the University of Rochester Medical Center. Environment -The Medical Center has the experienced clinical researchers and requisite resources to ensure Dr. Lerner's success. In particular, a Consultant Committee will provide support for this proposal. The Clinical Trials Coordinating Center and Strong Children's Research Center will lend additional expertise. Research - Neurologic complications secondary to cerebrovascular disease are prevalent in children with homozygous sickle cell disease. It is hypothesized that daily low-dose aspirin therapy will safely diminish the incidence and progression of cognitive deficit as well as the predisposition to overt and silent stroke in these children. In order to maximize the design of a future Phase III trial to test this hypothesis, a pilot study has been approved by the NINDS. Its primary objective is to evaluate the safety and tolerability of aspirin. This K24 application proposes additional studies to augment the trial. These will investigate the prognostic relationship of laboratory markers of inflammation and coagulation to the incidence and progression of cerebrovascular damage. Subsequent investigations will evaluate the change secondary to aspirin therapy in those laboratory parameters with prognostic capability. Later proposed studies include investigations regarding magnetic resonance imaging in children with documented stroke on chronic transfusion therapy and tailored educational modifications to improve performance in children with neurocognitive deficits. Mentorship -The principle investigator will provide clinical research training to qualified MDs with a particular interest in pediatric cerebrovascular disease, hemoglobinopathies, and/or neurocognitive function. Trainees will be recruited from: Pediatric Hematology/Oncology fellows, Masters in Public Health (clinical track) candidates, participants in programs of the Department of Neurology, and residents. The program will include core educational instruction, seminar series, and individualized guidance. Trainees will participate in the conduct of the pilot trial and a multi-center phase III study, should this be funded. The additional studies proposed in this application will serve as initial individual clinical research opportunities. Outcome measures will be used to assess the efficacy of the mentoring program.

描述（由申请人提供）：候选人-Lerner博士是一名儿科血液学家/肿瘤学家，最近将其重点转向以患者为导向的研究。她已经完成了公共卫生硕士学位的课程，并与罗切斯特大学医学中心经验丰富的临床研究人员建立了工作关系。环境-医疗中心拥有经验丰富的临床研究人员和必要的资源，以确保博士Lerner的成功。特别是，一个顾问委员会将为这项建议提供支持。临床试验协调中心和强儿童研究中心将提供额外的专业知识。研究-脑血管病继发的神经系统并发症在纯合子镰状细胞病患儿中很常见。据推测，每日低剂量阿司匹林治疗将安全地减少这些儿童的认知缺陷的发生率和进展，以及显性和隐性卒中的易感性。为了最大限度地提高未来III期试验的设计来验证这一假设，NINDS已经批准了一项试点研究。其主要目的是评估阿司匹林的安全性和耐受性。本K24申请提出了额外的研究以增强试验。这些将研究炎症和凝血实验室标志物与脑血管损伤的发生和进展的预后关系。随后的研究将评估继发于阿司匹林治疗的那些具有预后能力的实验室参数的变化。后来提出的研究包括关于长期输血治疗的记录卒中儿童的磁共振成像的调查，以及为改善神经认知缺陷儿童的表现而进行的量身定制的教育修改。指导-主要研究者将为对儿科脑血管疾病、血红蛋白病和/或神经认知功能特别感兴趣的合格医学博士提供临床研究培训。受训人员将从以下人员中招募：儿科血液学/肿瘤学研究员，公共卫生硕士（临床轨道）候选人，神经病学系计划的参与者和居民。该计划将包括核心教育指导，研讨会系列和个性化指导。如果获得资助，受训人员将参与试点试验和多中心III期研究。本申请中提出的其他研究将作为初始个体临床研究机会。结果的措施将被用来评估辅导计划的有效性。